Johnson & Johnson (NYSE:JNJ) Shares Sold by DORCHESTER WEALTH MANAGEMENT Co

DORCHESTER WEALTH MANAGEMENT Co lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 73,643 shares of the company’s stock after selling 895 shares during the period. Johnson & Johnson makes up approximately 2.1% of DORCHESTER WEALTH MANAGEMENT Co’s investment portfolio, making the stock its 15th largest position. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Johnson & Johnson were worth $11,935,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Index Fund Advisors Inc. acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $275,000. Impact Partnership Wealth LLC boosted its stake in shares of Johnson & Johnson by 1.8% in the third quarter. Impact Partnership Wealth LLC now owns 7,160 shares of the company’s stock valued at $1,160,000 after purchasing an additional 126 shares during the period. Grimes & Company Inc. grew its holdings in shares of Johnson & Johnson by 1.8% in the third quarter. Grimes & Company Inc. now owns 100,742 shares of the company’s stock valued at $16,326,000 after purchasing an additional 1,776 shares in the last quarter. Asset Planning Services Inc. LA ADV lifted its holdings in Johnson & Johnson by 2.4% during the 3rd quarter. Asset Planning Services Inc. LA ADV now owns 36,104 shares of the company’s stock worth $5,851,000 after buying an additional 850 shares in the last quarter. Finally, Boyd Watterson Asset Management LLC OH grew its stake in shares of Johnson & Johnson by 5.3% in the third quarter. Boyd Watterson Asset Management LLC OH now owns 25,047 shares of the company’s stock worth $4,059,000 after acquiring an additional 1,261 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. TD Cowen lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Sanford C. Bernstein raised their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Trading Down 1.7 %

NYSE:JNJ opened at $160.88 on Friday. The company has a market capitalization of $387.28 billion, a PE ratio of 23.28, a P/E/G ratio of 2.90 and a beta of 0.52. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The stock’s 50 day moving average price is $163.38 and its 200 day moving average price is $154.98. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.46%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the firm posted $2.66 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.08%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.